BMY vs LEGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BMY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and LEGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and LEGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is navigating a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.

Full BMY guide

Legend Biotech is a global cell-therapy company best known for CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. It develops and commercializes CARVYKTI in a 50/50 profit-and-cost-sharing collaboration with Johnson & Johnson, so Legend's reported revenue shows up largely as collaboration and license income rather than direct product sales. The company also runs an earlier-stage pipeline of other cell therapies and solid-tumor programs, but CARVYKTI drives essentially all of the current commercial narrative.

Full LEGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BMY drivers: New product portfolio ramp; Oncology and immunology depth.
• LEGN drivers: CARVYKTI commercial ramp; Move to earlier lines of therapy.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For LEGN, legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; LEGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and LEGN guides.

BMY. Bristol Myers tends to trade at a low forward earnings multiple relative to large-cap pharma peers, reflecting market skepticism about its ability to replace patent-cliff revenue. The high dividend yield and strong free cash flow are the bull-case anchors, while the depressed valuation reflects the bear case that legacy declines outrun newer products.

LEGN. LEGN trades as a high-multiple growth biotech whose revenue is recognized mainly as collaboration and license income under the J&J profit split, distinct from CARVYKTI's roughly $1.9 billion in 2025 global net trade sales. The company is approaching adjusted breakeven while still reporting losses, so the valuation reflects expectations for continued CARVYKTI growth rather than current earnings. Wall Street price targets vary widely, underscoring how much hinges on the pace of the ramp.

Headline figures (approximate, early 2026): BMY shows revenue (ttm) ~$48 billion, operating margin ~20% (varies with acquisition charges), net income (ttm) volatile, pressured by large acquisition write-offs, dividend yield ~4-5%; LEGN shows revenue (ttm, collaboration/license) ~$1.1B, carvykti net trade sales (fy2025, global) ~$1.9B, q1 2026 total revenue ~$305M, fy2025 adjusted net loss ~$33M.

BMY and LEGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and LEGN exposure against your real portfolio. It is not an investment adviser.